Q1 Earnings Forecast for DNLI Issued By HC Wainwright

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Wednesday, November 4th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.60) per share for the quarter. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Denali Therapeutics’ Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.57) EPS and Q4 2027 earnings at ($0.53) EPS.

A number of other brokerages also recently issued reports on DNLI. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 price target on the stock. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a research note on Wednesday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, Morgan Stanley raised their price target on shares of Denali Therapeutics from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $36.15.

Denali Therapeutics Stock Up 7.8%

Denali Therapeutics stock opened at $20.96 on Thursday. Denali Therapeutics has a 12 month low of $13.75 and a 12 month high of $27.30. The stock has a fifty day simple moving average of $20.35 and a two-hundred day simple moving average of $21.25. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of -12.12 and a beta of 1.08.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.64. The business had revenue of $17.78 million during the quarter, compared to the consensus estimate of $12.67 million. During the same period last year, the company posted ($0.74) earnings per share.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the transaction, the insider directly owned 281,763 shares in the company, valued at $7,063,798.41. This trade represents a 1.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 9.70% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Several large investors have recently modified their holdings of DNLI. Alps Advisors Inc. lifted its holdings in Denali Therapeutics by 32.0% in the third quarter. Alps Advisors Inc. now owns 211,772 shares of the company’s stock valued at $4,377,000 after acquiring an additional 51,394 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Denali Therapeutics in the third quarter worth about $169,000. VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in shares of Denali Therapeutics by 237.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 48,300 shares of the company’s stock valued at $998,000 after purchasing an additional 34,000 shares during the period. Manchester Capital Management LLC grew its stake in shares of Denali Therapeutics by 5,505.6% during the 3rd quarter. Manchester Capital Management LLC now owns 2,018 shares of the company’s stock valued at $42,000 after purchasing an additional 1,982 shares during the period. Finally, E. Ohman J or Asset Management AB increased its position in shares of Denali Therapeutics by 3.1% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 165,000 shares of the company’s stock valued at $3,411,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Key Headlines Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH sales and Q4 outlook: Net product revenue reached $17.8 million in the second full commercial quarter. Denali expects Q4 2026 product revenue of $30 million to $32 million, signaling substantial near-term growth. Denali Q3 2026 financial results and business highlights
• Positive Sentiment: Revenue beat estimates: Q3 revenue of $17.78 million topped analyst expectations of $12.67 million. The company also reported a $70.1 million net income for the quarter. Denali Therapeutics soars on earnings beat
• Positive Sentiment: Analyst targets raised: Morgan Stanley lifted its target to $42 and maintained Overweight; Wedbush raised its target to $24 and maintained Outperform. BTIG reaffirmed Buy with a $39 target. The higher targets reflect analyst optimism, though they are not guarantees of future performance. Read More., Read More., Read More.
• Positive Sentiment: Pipeline and balance sheet: Denali said a 2027 BLA filing for zafinofusp is on track and expects data from five TransportVehicle programs in 2027. Cash, equivalents and marketable securities totaled $1.0 billion. Denali Q3 2026 financial results and business highlights
• Neutral Sentiment: Earnings quality context: Q3 net income included a one-time $194 million gain from selling a Priority Review Voucher, so the reported profit is not solely reflective of recurring operations. Denali Q3 2026 financial results and business highlights

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.